论文部分内容阅读
随机选择６４例肾移植患者采用酶联免疫吸附法检测其血浆粘附分子ＧＭＰ－１４０水平，以探讨肾移植患者血浆ＧＭＰ－１４０水平的变化及意义。结果环孢素肾中毒组的血浆ＧＭＰ－１４０水平中度升高（２９２±９９μｇ／Ｌ），与移植肾功能稳定组比较（１１４±３０μｇ／Ｌ）差异显著（Ｐ＜０．０１）；排斥组（５１５±１８７μｇ／Ｌ）与稳定组及环孢素肾中毒组比较，差异显著（Ｐ＜０．０１）；肾功能稳定但并发感染者血浆ＧＭＰ－１４０水平（５３５±１７２μｇ／Ｌ）与急性排斥组比较差异不显著。结果提示测定血浆ＧＭＰ－１４０的变化对肾移植术后的监测具有一定的意义。
Sixty-four renal transplant recipients were randomly selected to detect plasma GMP-140 levels by enzyme-linked immunosorbent assay (ELISA) to investigate the changes and significance of GMP-140 in renal transplant recipients. Results The level of plasma GMP-140 in patients with cyclosporine nephrotoxicity was moderate (292 ± 99μg / L), which was significantly different from that in the stable renal transplantation group (114 ± 30μg / L) (P <0.01) (515 ± 187μg / L) was significantly higher than those in the stable group and the cyclosporine nephritis group (P <0.01). The levels of plasma GMP-140 in the patients with stable renal function (535 ± 172μg / L) Acute rejection group was no significant difference. The results suggest that the determination of plasma GMP-140 changes after renal transplantation has a certain significance.